204 results about "Encephalitis" patented technology

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF). The methods provide for efficiently removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents. The invention finds use as a diagnostic, therapeutic and drug delivery platform for a variety of diseases affecting the CNS by accessing the CSF space. Exemplified disease conditions treatable by the present CSF processing systems and methods include, but are not limited to: Cerebral Vasospasm, Guillain Bane Syndrome, illustrating multi-lumen lumbar approach Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Stroke, Cancer affecting the brain or spinal cord, Prion disease, Encephalitis from various causes, Meningitis from various causes, diseases secondary to enzymatic or metabolic imbalances, Biological Warfare, etc. For the first time, the present invention offers patients a disease-modifying, disruptive technology treatment platform that addresses the known disease pathogenesis of a number of neurologic conditions to which there are presently limited and ineffective treatment options.

The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gl, Us9, or other proteins.

The invention discloses a multiplex PCR detection kit for 12 encephalitis virus nucleic acids and application thereof. The multiplex PCR detection kit comprises primers used for amplifying specific gene sites of the following 12 encephalitis virus: JeV, HTLV1, WNV, HSV1, HSVII, HHV6, JCV, HTLV2, BBF, HCMV, EBV and VZV. The detection kit has the advantages of capacity of realizing multiplex detection, high sensitivity and rapidness and convenience in usage. Moreover, specific primer sequences are employed to guarantee reliability of detection results. A detection method is simple to operate and labor-saving and time-saving; detection flux is great, and cost for reagent consumables is low; nucleic acids extracted from encephalitis pathogen samples can be directly detected; and requirements on a detection platform and manual technique levels are low, so the method can be extensively popularized in conventional detection.

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

A Chinese medicine for treating chronic dementia, sanile dementia, vanular dementia and AD is prepared from 7 Chinese-medicinal materials including astragalus root, red sage root, Chuan-xiong rhizome, borneol, etc. Its advantages are high curative effect and quickly taking its effect.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The invention relates to the pharmacy field, concretely relates to a use of a series of pentacyclic triterpene compounds as enterovirus EV71 inhibitors, and especially relates to an application in the preparation of medicines for preventing and treating EV71 infection induced hand-foot-and-mouth diseases and complications thereof, such as synanche, myocarditis, pulmonary edema, encephalitis, herpes, septicemia, hypertension, hyperglycemia, cognitive function disorder, poliomyelitis-like paralysis and many nerve system associated diseases. The invention also discloses medicinal compositions of the series of the pentacyclic triterpene compounds as enterovirus EV71 inhibitors.

The invention discloses a recombinant baby hamster kidney cell line (BHK 21) capable of stably expressing encephalitis B virus PrM/M-E protein, and more particularly, the recombinant cell line capable of expressing the PrM/M-E protein is BHK-JEV-ME and is preserved in the China General Microbiological Culture Collection Center (CGMCC) with the culture preservation number of CGMCC No. 5263. The invention also discloses a method for preparing the recombinant cell line and the application of the recombinant cell line in the preparation of encephalitis B prevention vaccine.

The invention discloses an immunologic diagnosis kit for detecting dengue virus NS1 antigen and application thereof. The kit comprises a capturing antibody and a detecting body combined with a marker, and the kit is characterized in that the capturing antibody consists of a monoclonal antibody 2E8A5, a monoclonal antibody DV2M6 and a monoclonal antibody 4B14A1, the detecting antibody is a monoclonal antibody 3B1A15, and the marker can be biotin, horseradish peroxidase, alkaline phosphatase, colloidal gold or fluorescein. The kit can specifically detect NS1 proteins of four serotype dengue viruses and does not have cross reaction with other viruses of flavivirus system, such as flavivirus and encephalitis B virus, the sensitivity of the kit is at least four times higher than that of detection of foreign commodity kits, and the kit can efficiently reduce the omission factor of the clinical application.

Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ_(1-42), block Aβ_(1-42)-induced neuronal death, block Aβ_(1-42)-induced [Ca²⁺]_i dysfunction in neurons, block Aβ_(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell. CeONP can also be effective in treating conditions involving toxic exposures to compounds that induce mitochondrial dysfunction, such as rotenone, cyanide, carbon monoxide, polychlorinated biphenyls (PCBs) and other mitochondrial toxins.

The invention relates to the field of traditional Chinese medicine, and discloses a repair traditional Chinese medicine used for treating blood cell infected by flaviviridae. The traditional Chinese medicine is prepared from: by weight, herba tubocapsici anomali 30g-80g, cymbopogon citratus 20g-50g, camellia flower 10g-30g, citrus aurantium flower 10g-30g, bitter gourd 20g-50g, mint 20g-50g, phellodendron amurense 10g-30g, cypress leaf 10g-30g, salix leaf 10g-30g, persimmon leaf 15g-35g, perilla nankinensis 10g-20g, radix sophorae flavescentis 30g-60g, eleusine indica 25g-80g, syzygium aromaticum 10g-30g, lonicera japonica 30g-80g, agastache rugosus 20g-50g, portulaca oleracea 10g-30g, glycyrrhiza 5g-15g, chrysanthemum 10g-35g, and foeniculum vulgare 10g-35g. The traditional Chinese medicine has cure effect of the diseases such as dengue, Zika virus, encephalitis, hepatitis and liver cancer infected by flaviviridae spreading, can treat and repair the blood cell from the source, has prophylaxis and treatment effect on flaviviridae diseases, is without any toxicity and side effects, and can improve the cure rate and cure efficiency of patients.

The invention relates to the technical field of biology, in particular to a method for producing a human diploid cell encephalitis B inactivated vaccine. The method sequentially comprises the following steps of: resuscitating and subculturing a human diploid cell strain; culturing the human diploid cell strain by using a multi-stage bioreactor; inoculating an encephalitis B virus strain, and performing virus multiplication culture; harvesting a virus culture solution; and inactivating the virus culture solution, performing ultrafiltration, purifying, adding a glycoprotein protective agent, and preparing the vaccine. Human diploid cells are used as a cell matrix, so that the vaccine is safe and is free from exogenous factor pollution; the human diploid cells are cultured by the bioreactor through stage-by-stage linear amplification, so that the large-scale production of the vaccine with low cost, high quality, safety and stability is easy to implement; and the titer of the virus harvested solution is subjected to sampling inspection every day, so that the high expression of the harvested virus culture is ensured, and production quality is ensured.

The invention relates to a method capable of detecting common viruses of arbovirus encephalitis. The invention also relates to an amplification primer and an extension primer which are used for detecting the common viruses of arbovirus encephalitis, and a kit containing the primers.